Table 2. Stratified Cox proportional hazards model for overall survival (OS) (N=924).
| Covariate | Estimate | s.e. | HR | 95% CI | P-value |
|---|---|---|---|---|---|
| HER2-positive treated tumour | −0.2931 | 0.0995 | 0.7459 | 0.6137–0.9065 | 0.0032 |
| Gender, female | 0.0409 | 0.0759 | 1.0141 | 0.8977–1.2088 | 0.5902 |
| Lauren | 0.2032 | ||||
| Intestinal | — | — | Ref. | Ref. | — |
| Diffuse | 0.1454 | 0.0841 | 1.1565 | 0.9807–1.3637 | 0.0838 |
| Mixed | 0.1295 | 0.1536 | 1.1382 | 0.8423–1.5381 | 0.3990 |
| ECOG-PS | <0.0001 | ||||
| 0 | — | — | Ref. | Ref. | — |
| 1 | 0.1639 | 0.0880 | 1.1780 | 0.9914–1.3998 | 0.0624 |
| ⩾2 | 0.7536 | 0.1173 | 2.1246 | 1.6882–2.6738 | <0.0001 |
| Bone metastases | 0.2727 | 0.1198 | 1.3135 | 1.0386–1.6611 | 0.0228 |
| Number of metastatic sites ⩾3 | 0.2387 | 0.0762 | 1.2695 | 1.0934–1.4741 | 0.0017 |
| Ascites | 0.013 | ||||
| No | — | — | Ref. | Ref. | — |
| Mild | 0.1690 | 0.0968 | 1.1841 | 0.9794–1.4315 | 0.0806 |
| Moderate–severe | 0.3300 | 0.1247 | 1.3909 | 1.0893–1.7760 | 0.0081 |
| Grade G2–G3 | 0.2363 | 0.1194 | 1.2665 | 1.0022–1.6005 | 0.0478 |
| NLR | 0.032 | ||||
| <4 | — | — | Ref. | Ref. | — |
| 4–7.9 | 0.1895 | 0.0783 | 1.2086 | 1.0366–1.4091 | 0.0155 |
| ⩾8 | 0.3783 | 0.1362 | 1.4598 | 1.1177–1.9064 | 0.0055 |
| Serious complications | 0.0178 | 0.1099 | 1.0179 | 0.7794–1.3294 | 0.8714 |
| Chronic comorbidities ⩾2 | 0.1090 | 0.0989 | 1.1151 | 0.9186–1.3537 | 0.2704 |
| Locally advanced unresectable | −0.2039 | 0.1681 | 0.8155 | 0.5866–1.1338 | 0.2253 |
Abbreviations: CI=confidence interval; ECOG-PS=Eastern Cooperative Oncology Group Performance Status; NLR=neutrophil-to-lymphocyte ratio; Ref=reference value; s.e.=standard error (of estimate).